An effective malaria vaccine could prove to be the most cost-effective and efficacious means
of preventing severe disease and death from malaria. In an endeavor to identify novel …

Background Plasmodium falciparum cysteine-rich protective antigen (Pf CyRPA) is an
invasion complex protein essential for erythrocyte invasion. In contrast to several previously …

Background The pathogenesis of malaria is primarily associated with blood-stage infection
and there is strong evidence that antibodies specific for parasite blood-stage antigens can …

Abstract The Plasmodium falciparum (Pf) cysteine-rich protective antigen (Pf CyRPA) has
emerged as a promising blood-stage candidate antigen for inclusion into a broadly cross …

The highly conserved Plasmodium falciparum cysteine-rich protective antigen (PfCyRPA) is
a key target for next-generation vaccines against blood-stage malaria. PfCyRPA constitute …

Plasmodium falciparum cysteine-rich protective antigen (CyRPA) is a conserved component
of an essential erythrocyte invasion complex (RH5/Ripr/CyRPA) and a target of potent cross …

Plasmodium falciparum causes malaria in humans with over 450,000 deaths annually. The
asexual blood stage involves invasion of erythrocytes by merozoites, in which they grow and …

The leading malaria vaccine candidate, RTS, S, based on the Plasmodium falciparum
circumsporozoite protein (CSP), will likely be the first publicly adopted malaria vaccine …

The N-terminal domain of the circumsporozoite protein (CSP) has been largely neglected in
the search for a malaria vaccine in spite of being a target of inhibitory antibodies and …

Introduction A safe and effective vaccine will likely be necessary for the control or
eradication of malaria which kills 400,000 annually. Our most advanced vaccine candidate …